Point72 Middle East FZE’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-19,500
Closed -$11.4M 757
2023
Q4
$11.4M Buy
19,500
+4,300
+28% +$2.51M 0.34% 52
2023
Q3
$8.16M Buy
+15,200
New +$7.83M 0.27% 95
2023
Q2
Sell
-10,100
Closed -$3.47M 1844
2023
Q1
$3.47M Buy
10,100
+6,400
+173% +$2.16M 0.12% 220
2022
Q4
$1.35M Buy
+3,700
New +$1.31M 0.06% 418

Other funds holding LLY

Point72 Middle East FZE's LLY Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Eli Lilly (LLY) in Q1 2024, closing a stake of 16,924 shares — an estimated $9.87M sold.

Point72 Middle East FZE first reported a position in LLY in Q2 2023 and held it in 2 quarters. The position peaked at $9.87M in Q4 2023. 3,461 funds tracked by Wall St. Rank hold LLY as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Eli Lilly position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 16,924 Eli Lilly shares in Q1 2024, an estimated $9.87M.
  • Point72 Middle East FZE first reported a position in Eli Lilly in Q2 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's Eli Lilly position peaked at $9.87M in Q4 2023.
  • 3,461 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.